Theriva Biologics Dirección

Dirección controles de criterios 2/4

Theriva Biologics' El consejero delegado es Steve Shallcross , nombrado en Jun 2015, tiene un mandato de 8.5 años. la remuneración anual total es $1.19M , compuesta por 49.1% salario y 50.9% primas, incluidas acciones y opciones de la empresa. posee directamente 1.47% de las acciones de la empresa, por valor de $145.00K . La antigüedad media del equipo directivo y del consejo de administración es de 8.5 años y 7.3 años respectivamente.

Información clave

Steve Shallcross

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO	48.3%
Permanencia del CEO	8.8yrs
Participación del CEO	1.5%
Permanencia media de la dirección	8.8yrs
Promedio de permanencia en la Junta Directiva	7.6yrs

Actualizaciones recientes de la dirección

Recent updates

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Mar 07

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

Feb 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Shallcross en comparación con los beneficios de Theriva Biologics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$1m	US$614k	-US$18m
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$1m	US$585k	-US$20m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$17m
Mar 31 2022	n/a	n/a	-US$16m
Dec 31 2021	US$1m	US$585k	-US$23m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$21m
Dec 31 2020	US$1m	US$565k	-US$13m
Sep 30 2020	n/a	n/a	-US$13m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$1m	US$550k	-US$16m
Sep 30 2019	n/a	n/a	-US$28m
Jun 30 2019	n/a	n/a	-US$26m
Mar 31 2019	n/a	n/a	-US$27m
Dec 31 2018	US$963k	US$489k	-US$25m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$22m
Mar 31 2018	n/a	n/a	-US$22m
Dec 31 2017	US$799k	US$347k	-US$22m

Compensación vs. Mercado: Steve($USD1.19M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de Steve ha aumentado mientras la empresa no es rentable.

CEO

Steve Shallcross (62 yo)

8.8yrs

Permanencia

US$1,271,913

Compensación

Mr. Steven A. Shallcross, also known as Steve, CPA, was an Independent Director of Forza X1, Inc. since December 2021. He served as Independent Director at Twin Vee Powercats Co. since April 8, 2021 until...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Shallcross	CEO, CFO	8.8yrs	US$1.27m	1.46% $ 112.4k
Vince Wacher	Head of Product & Corporate Development	no data	sin datos	sin datos
Michael Kaleko	Senior Vice President of Research & Development	11.5yrs	sin datos	sin datos
Ramon Alemany	Senior VP of Discovery & Chairman of Scientific Advisory Board	less than a year	sin datos	sin datos
Lara Guzman	Senior Director of Project Operations	no data	sin datos	sin datos

8.8yrs

Permanencia media

Equipo directivo experimentado: TOVXEl equipo directivo de la empresa es veterano y experimentado (8.5 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Shallcross	CEO, CFO	5.3yrs	US$1.27m	1.46% $ 112.4k
Ramon Alemany	Senior VP of Discovery & Chairman of Scientific Advisory Board	1.9yrs	sin datos	sin datos
John Monahan	Independent Director	3.4yrs	US$110.51k	sin datos
Jeffrey Kraws	Independent Non-Executive Chairman	18.3yrs	US$216.88k	0.0038% $ 293.7
Mark Blumenkranz	Member of Scientific Advisory Board	1.9yrs	sin datos	sin datos
Jeffrey Wolf	Independent Director	18.3yrs	US$114.38k	sin datos
Curtis Donskey	Member of C Difficile Clinical Advisory Board	9.8yrs	sin datos	sin datos
Thomas Louie	Member of C Difficile Clinical Advisory Board	9.8yrs	sin datos	sin datos
Ciarán Kelly	Member of C Difficile Clinical Advisory Board	9.8yrs	sin datos	sin datos
Mark Wilcox	Chairman of C Difficile Clinical Advisory Board	9.8yrs	sin datos	sin datos
Richard Hodin	Member of Intestinal Alkaline Phosphatase Clinical Advisory Board	3.8yrs	sin datos	sin datos
Ennio Chiocca	Member of Scientific Advisory Board	1.9yrs	sin datos	sin datos

7.6yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de TOVX se considera experimentada (7.3 años de antigüedad promedio).

Theriva Biologics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

High number of new and inexperienced directors

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

High number of new and inexperienced directors

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Recent updates

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

New minor risk - Share price stability

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Theriva Biologics, Inc., Annual General Meeting, Oct 02, 2023

New minor risk - Shareholder dilution

New major risk - Market cap size

New minor risk - Share price stability

Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery

Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors

High number of new and inexperienced directors

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

Theriva Biologics, Inc. Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (Dsmc) Review in Phase 1B/2A Clinical Trial of Syn-004 (Ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck

Synthetic Biologics, Inc., Annual General Meeting, Sep 30, 2022

Synthetic Biologics, Inc. announced that it expects to receive $3 million in funding from MSD Partners, L.P.

Synthetic Biologics, Inc. Notifies Clearance of Safety Evaluation Period

High number of new and inexperienced directors

Synthetic Biologics, Inc. Reports Positive Safety Data on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Price target increased to US$1.63

Synthetic Biologics, Inc. Announces Peer-Reviewed Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients with Advanced Solid Tumors

Synthetic Biologics, Inc. (NYSEAM:SYN) signed a definitive agreement to acquire VCN Biosciences SL from Grifols Innovation and New Technologies Limited and others for $85.6 million.

Synthetic Biologics Provides Update on Syn-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial

Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards

David Lazar Just Bought 13% More Shares In Synthetic Biologics, Inc. (NYSEMKT:SYN)

Synthetic Biologics, Inc. Announces Clinical Development and Operational Update

Insider recently bought US$174k worth of stock

Synthetic Biologics, Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

New 90-day high: US$1.17

Who Has Been Buying Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares?

New 90-day high: US$0.50

Synthetic Biologics, Inc. Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol

Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American

Synthetic Biologics, Inc. Announces Executive Changes

Synthetic Biologics, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.31

New 90-day low: US$0.31

Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2B Clinical Study of SYN-010 in IBS-C Patients

New 90-day low: US$0.45

Synthetic Biologics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - US$0.71

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad